- Home
- SLS vs EDAP Comparison
SLS vs EDAP Comparison
Compare SLS & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- EDAP
- Stock Information
- Founded
- SLS 2012
- EDAP 1979
- Country
- SLS United States
- EDAP France
- Employees
- SLS N/A
- EDAP N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SLS Health Care
- EDAP Health Care
- Exchange
- SLS Nasdaq
- EDAP Nasdaq
- Market Cap
- SLS 70.1M
- EDAP 81.6M
- IPO Year
- SLS N/A
- EDAP 1997
- Fundamental
- Price
- SLS $1.06
- EDAP $2.17
- Analyst Decision
- SLS
- EDAP Strong Buy
- Analyst Count
- SLS 0
- EDAP 1
- Target Price
- SLS N/A
- EDAP $19.00
- AVG Volume (30 Days)
- SLS 1.4M
- EDAP 70.3K
- Earning Date
- SLS 11-13-2024
- EDAP 11-07-2024
- Dividend Yield
- SLS N/A
- EDAP N/A
- EPS Growth
- SLS N/A
- EDAP N/A
- EPS
- SLS N/A
- EDAP N/A
- Revenue
- SLS N/A
- EDAP $70,722,730.00
- Revenue This Year
- SLS N/A
- EDAP $6.96
- Revenue Next Year
- SLS N/A
- EDAP $15.53
- P/E Ratio
- SLS N/A
- EDAP N/A
- Revenue Growth
- SLS N/A
- EDAP 12.17
- 52 Week Low
- SLS $0.50
- EDAP $2.00
- 52 Week High
- SLS $1.72
- EDAP $8.50
- Technical
- Relative Strength Index (RSI)
- SLS 55.79
- EDAP 45.70
- Support Level
- SLS $0.87
- EDAP $2.12
- Resistance Level
- SLS $1.01
- EDAP $2.26
- Average True Range (ATR)
- SLS 0.08
- EDAP 0.16
- MACD
- SLS 0.01
- EDAP -0.01
- Stochastic Oscillator
- SLS 73.08
- EDAP 27.42
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.